Login
$COYA
$2.96 -$0.04 (1.33%) After hours

$COYA SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disord...

14 Oct 2026 8-K: Other Events

On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotr...

05 Oct 2026 8-K: Other Events

On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating ...

15 Sep 2026 8-K: Other Events

On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100th) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302,...

11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neu...

07 Aug 2026 8-K/A: Departure/Election of Directors or Officers; Compensation

This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Coya Therapeutics, Inc. (the “Company”) dated March 29, 2026 and filed with the Securities and Exchange Commission on April 2...

27 Jul 2026 SCHEDULE 13G/A
25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 25, 2026, Coya Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (i) the election of two Class I directors and (ii) the ratificatio...

13 May 2026 ARS
13 May 2026 DEFA14A
13 May 2026 Proxy statement: annual meeting on June 25, 2026
12 May 2026 8-K: Entry into a Material Definitive Agreement

Coya Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

12 May 2026 424B5
12 May 2026 10-Q
12 May 2026 8-K: Results of Operations and Financial Condition; Other Events

HOUSTON, TX., May 12, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurod...

09 Apr 2026 Form 4: Pavao Mark H, Director

Granted 10,000 Stock Option (right to buy)

09 Apr 2026 Form 3: Pavao Mark H, Director

No securities owned

02 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Separation and General Release Agreement (“Agreement”) confirms the terms of the separation of Howard Berman’s (“you” or “your”) employment with Coya Therapeutics, Inc. (the “Company”), including the consideration described below in...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support